CA2359110A1 - Nouveau traitement - Google Patents

Nouveau traitement Download PDF

Info

Publication number
CA2359110A1
CA2359110A1 CA002359110A CA2359110A CA2359110A1 CA 2359110 A1 CA2359110 A1 CA 2359110A1 CA 002359110 A CA002359110 A CA 002359110A CA 2359110 A CA2359110 A CA 2359110A CA 2359110 A1 CA2359110 A1 CA 2359110A1
Authority
CA
Canada
Prior art keywords
hepatitis
pharmaceutical pack
vaccine
antiviral agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359110A
Other languages
English (en)
Inventor
Ronald James Boon
Pierre G. Vandepapeliere
Gillian Frances Atkinson
Martine Anne Cecile Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359110A1 publication Critical patent/CA2359110A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Cette invention a trait à un produit pharmaceutique contenant, comme ingrédients actifs (1), un agent antiviral agissant contre le virus de l'hépatite B et (2), un vaccin convenant à la prophylaxie ou au traitement de l'infection par virus de l'hépatite B. Ces ingrédients actifs sont utilisés simultanément ou à la suite. Les composants préférés sont un analogue de nucléoside en tant qu'agent antiviral ainsi qu'un vaccin contre le virus de l'hépatite B renfermant un antigène de surface du virus de l'hépatite B.
CA002359110A 1999-01-12 1999-12-21 Nouveau traitement Abandoned CA2359110A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
GB9900630.6 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (fr) 1999-01-12 1999-12-21 Nouveau traitement

Publications (1)

Publication Number Publication Date
CA2359110A1 true CA2359110A1 (fr) 2000-07-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359110A Abandoned CA2359110A1 (fr) 1999-01-12 1999-12-21 Nouveau traitement

Country Status (19)

Country Link
EP (1) EP1140163A2 (fr)
JP (1) JP2002534438A (fr)
KR (1) KR20010090011A (fr)
CN (1) CN1391482A (fr)
AR (1) AR022250A1 (fr)
AU (1) AU760574B2 (fr)
BR (1) BR9916893A (fr)
CA (1) CA2359110A1 (fr)
CO (1) CO5241355A1 (fr)
CZ (1) CZ20012544A3 (fr)
HK (1) HK1041434A1 (fr)
HU (1) HUP0105070A2 (fr)
IL (1) IL144186A0 (fr)
NO (1) NO20013337L (fr)
NZ (1) NZ512890A (fr)
PL (1) PL349347A1 (fr)
TR (1) TR200102024T2 (fr)
WO (1) WO2000041463A2 (fr)
ZA (1) ZA200105690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
WO2020134682A1 (fr) * 2018-12-24 2020-07-02 南京远大赛威信生物医药有限公司 Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée
CN117120088A (zh) * 2021-04-07 2023-11-24 电化株式会社 佐剂活性增强剂和佐剂组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
ES2273482T3 (es) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.

Also Published As

Publication number Publication date
IL144186A0 (en) 2002-05-23
HUP0105070A2 (hu) 2002-04-29
WO2000041463A3 (fr) 2000-11-09
NO20013337L (no) 2001-08-17
NZ512890A (en) 2003-09-26
CZ20012544A3 (cs) 2002-01-16
KR20010090011A (ko) 2001-10-17
TR200102024T2 (tr) 2001-12-21
PL349347A1 (en) 2002-07-15
JP2002534438A (ja) 2002-10-15
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (fr) 2000-07-20
CN1391482A (zh) 2003-01-15
ZA200105690B (en) 2002-09-25
AU2100900A (en) 2000-08-01
AU760574B2 (en) 2003-05-15
EP1140163A2 (fr) 2001-10-10
CO5241355A1 (es) 2003-01-31
AR022250A1 (es) 2002-09-04
HK1041434A1 (zh) 2002-07-12
BR9916893A (pt) 2001-11-20

Similar Documents

Publication Publication Date Title
JP3530526B2 (ja) ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン
AU760574B2 (en) Novel treatment
Ocama et al. Hepatitis B virus infection: current status
JP3470719B2 (ja) ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン
JP4126067B2 (ja) アジュバント組成物
AP408A (en) Vaccine composition containing adjuvants.
JP4510283B2 (ja) 併合ワクチン組成物
Dupont et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine
US9878035B2 (en) Hepatitis B vaccine
KR19980702480A (ko) Ｂ형 간염 백신
JPH08508722A (ja) ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
CN1515245A (zh) 含有皂苷和固醇的疫苗
WO2015196935A1 (fr) Composition pharmaceutique contenant un oligonucléotide cpg
Fernández et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
JP5138843B2 (ja) 新規組成物
MXPA01007112A (en) Novel treatment
Huang et al. New advances in hepatitis B vaccination for adults
Lu et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens
KR20210151047A (ko) B형 간염 치료를 위한 면역원성 조성물
JP2022516041A (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
CN109219449B (zh) 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
US7144703B2 (en) Composition
Sangar et al. NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE (V503/GARDASIL9®): A REVIEW
Vanlandschoot et al. A temperature-dependent inhibitory activity of serum on the capacity of Saccharomyces cerevisiae-derived hepatitis B surface antigen to bind to monocytes

Legal Events

Date Code Title Description
FZDE Discontinued